Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up
Université Laval · Municipal Institute for Medical Research · +24 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
484
total citations
- FWCI
- 59.37
- Percentile
- 100%
- References
- 23
Citations per year
Authors
20Topics & keywords
Topics
Keywords
- Medicine
- Docetaxel
- Urothelial cancer
- Paclitaxel
- Pembrolizumab
- Oncology
- Internal medicine
- Cancer
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- AAmgen
- BSBristol-Myers Squibb
- KCKidney Cancer Association
- ELEli Lilly and Company
- PPfizer
- AAstraZeneca
- GGlaxoSmithKline
- SSanofi
- ASAmerican Society of Clinical Oncology
- EExelixis
- IIncyte
- UPUroGen Pharma
- EEisai
- APAstellas Pharma
- FFFidia Farmaceutici
- IIpsen
- GGenentech
- ESEMD Serono
- MSMerck Sharp and Dohme
- FMFoundation Medicine
- NCNational Cancer Institute
- CCilag